Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Roche/Genentech's Avastin Continues to Garner the Greatest Physician-Reported Patient Share in DME Due to Its Low Relative Cost, According to Findings from Decision Resources Group
BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that, ahead of the anticipated label expansion of Regeneron's Eylea for diabetic macular edema (DME) in August 2014, over half of surveyed U.S. retinal specialists and general ophthalmologists currently prescribe this anti-vascular endothelial growth factor (VEGF) agent to their intravitreal (IVT)-treated DME patients. This significant increase in prescriber base compared with 12 months ago suggests that, in a market with only one approved therapy, physicians are eager to gain early experience with Eylea prior to approval. In fact, physicians already rate their satisfaction with Eylea similarly to that of the other anti-VEGF agents, Roche/Genentech's Avastin, the typical first-line treatment approach for DME, and Roche/Genentech's Lucentis 0.3 mg, which is the only FDA-approved therapy for DME.
Other key findings from the TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema 2014 (US) report:
Comments from Decision Resources Group Analyst Emma McFadden, Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.